Texas

Steps have been taken to safeguard the cancer center, including development of a cutting-edge approach to Enterprise Risk Management.

The survey showed that not surprisingly, patients by and large have negative views of the pharma industry when it comes to corporate responsibility and pricing -- mostly pricing.

Possibly in response to a trend for Medicare-for-All initiatives, healthcare stocks plunged this week. This largely affected companies like UnitedHealth, which fell 3.2%, Anthem, dropping by 6.8%, and Cigna Corp., sliding 5.1%.

Biotech, pharma and life science companies make appointments to leadership roles, with additions at Cerevance, Obsidian, KSQ, Lygos, and more.

In the first quarter of 2019, more than 30 life science companies* announced expansions, new locations, increased funding, new trial and product launches and various other news pointing to a growing industry.

The life science industry is continually making advancements in every area! We want to know what cool science innovations are currently in progress and the professionals behind them.

These days, when someone mentions blood-testing diagnostics systems that rely on a few drops of blood, first thoughts may head directly to the alleged fraud committed by the founder and chief executive officer of Theranos, Elizabeth Holmes. But despite that background, the co-founders of Microdrop believe they have a blood-testing diagnostics system that will bring levels of confidence back to the space due to validation from the scientific community.

Alcon CEO says the company is “poised to achieve sustainable growth and create long-term shareholder value as a standalone company.”

The recent CBRE Research report, “2019 U.S. Life Sciences Clusters” has two Texas metropolitan areas in its top-10 fastest-growing life sciences market. Houston ranked third, while Dallas/Ft. Worth ranked seventh. Let’s look at Dallas/Ft. Worth.

Public perception of the industry can be a bit confusing. Life Science Leader recently pulled together several biopharma executives for a round table discussion of the biopharma industry’s public perception—generally bad—and what might be able to do about it.